Enasidenib

The Basics

What is Enasidenib?

Used to treat acute myeloid leukemia (AML).

Brand names for Enasidenib

Idhifa

How Enasidenib is classified

Antineoplastic Agents, Enzyme Inhibitors, Isocitrate Dehydrogenase Inhibitors

Enasidenib During Pregnancy

Enasidenib pregnancy category

Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.

What we know about taking Enasidenib while pregnant

N/A

Taking Enasidenib While Breastfeeding

What are recommendations for lactation if you're taking Enasidenib?

No information is available on the clinical use of enasidenib during breastfeeding. Because enasidenib is 98.5% bound to plasma proteins and its active metabolite is 96.6% bound to plasma proteins, the amount in milk is likely to be low. However, the half-life of enasidenib is 137 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during enasidenib therapy and for at least 1 month after the end of therapy.

Maternal / infant drug levels

No information is available on the clinical use of enasidenib during breastfeeding. Because enasidenib is 98.5% bound to plasma proteins and its active metabolite is 96.6% bound to plasma proteins, the amount in milk is likely to be low. However, the half-life of enasidenib is 137 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during enasidenib therapy and for at least 1 month after the end of therapy.

Possible effects of Enasidenib on milk supply

Relevant published information was not found as of the revision date.

Possible alternatives to Enasidenib